News Wire ~ 3rd Party Press Release
Amulet Launches to Bring Powerful Detection Out of the Lab and Into the Hands...
Signature consumer wearable will begin shipping this summer.
Prota Therapeutics Achieves 51% Peanut Allergy Remission Rate in Kids with OIT Candidate
Children's ability to eat peanut freely and safely delivers meaningful improvement in quality of life for families and patients.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older...
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
Food Allergy Research and Education Names Permanent CEO
Extensive Search Culminates in New Leadership for Flagship Food Allergy Organization.
Plant Compound Shows Promise for Alleviating Food Allergies
Study uncovers new drug targets for treating other allergic disorders.
New Blood Test Simplifies the Diagnosis of Allergies and Can Help Predict the Success...
Test is painless, safe, reliable and scalable.
Adamis Issues Recall of SYMJEPI Emergency Epinephrine Device for Potential Manufacturing Defect
Specific batches identified in the article are being recalled.
Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA
AQST-109 is the first orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions including anaphylaxis.
FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven Peanut Allergy Therapy
Phase 2 study of candidate from Aravax will commence in the US and Australia.
Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients
Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.
